 |
|||||||||
 |
|||||||||
Vancouver: November 1, 2024 – TheNewswire – Xtacy Therapeutics Corp (CSE: XTCY) (Frankfurt: TT5) (OTC: XTCYF) (“the Company)
On October 28, 2024 Xtacy Therapeutics Corp. announced that it would be changing its name to Pegasus Mercantile Inc. (“Pegasus”) with a new stock symbol of “LOAN”. The CSE has confirmed that the effective date for the name and Symbol change will be at the open of markets on Monday, November 4, 2024. The new Cusip 70557Y105 will be effective at that time.
The Change marks a very important day for the Company with the new nomenclature. There are no changes to the Company strategy, however the investee companies have accelerated their business plans and their needs have changed. As an incubator and project generator, it is the role of Pegasus to help our clients increase their current valuations and grow organically to the next cycle in their lifespan. In prior press releases we indicated the intent of some portfolio companies to go public. Such disclosure indicates only their stated intentions to us, and each is responsible for making their unique way onto the public exchanges. The Pegasus team will take a more active role with the management of our current and new clients providing key advisory services. The Company will continue to provide business and financial plans, strategy, and merger/acquisition candidates with joint venture corporate partners and others involving financial and business related services.
“Our people invest in cutting edge biotechnology research and technology. Our strategy allows us to place investments into companies from start up to commercialization. We focus on scalability and differentiation which can potentially bring radical benefits to consumers and patients who need life changing treatments. We are extremely proud to be part of this evolving sector and look forward to bringing greater value to our shareholder base,” said Meris Kott, CEO.
About Pegasus Mercantile:
Pegasus is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.
For further information visit website:
Contact Meris Kott CEO
[email protected] (561)212-3323
Further information about the Company is available on www.SEDARplus.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2024 TheNewswire – All rights reserved.
